Peptide LibraryAmycretin
Also known as: Zenagamtide, NN9487, Unimolecular GLP-1/amylin agonist
Amycretin (also called Zenagamtide or NN9487) is an investigational GLP-1 + amylin unimolecular agonist. Amycretin is a single molecule that activates both the GLP-1 and amylin receptors, an approach sometimes described as unimolecular co-agonism — combining in one peptide the two satiety pathways that CagriSema addresses with two separate agents.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Investigational New Drug (IND)
- Evidence level
- Clinical Trial Evidence
- Human dose established
- Yes
- Administration Route
- Subcutaneous · Oral
- Frequency
- Once weekly (injection) or once daily (tablet)
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- GLP-1 receptorAmylin receptor
Research summary
Novo Nordisk unimolecular GLP-1 and amylin receptor agonist in oral and subcutaneous forms, advancing to Phase 3. Not FDA-approved. Distinct from CagriSema.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials4 reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Amycretin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Amycretin dosage evidence
Amycretin (now named zenagamtide) has no approved dosage. Human dosing comes from Novo Nordisk's phase 1 and phase 2 trials of two forms: once-weekly injections under the skin, escalated from 0.2–0.3 mg to maintenance doses of 0.4–60 mg, and once-daily tablets of 6–50 mg. In type 2 diabetes, weekly injections of 0.4–40 mg lowered HbA1c by 0.9 to 1.7 points over 36 weeks, and phase 3 trials are under way.
| Human dosing established | Yes |
|---|---|
| Route | Subcutaneous · Oral |
| Frequency | Once weekly (injection) or once daily (tablet) |
| Duration studied | 12–36 weeks in the published trials |
| Titration | Dose escalation every 4 weeks from a 0.2 mg starting dose to the maintenance dose in the subcutaneous phase 2 trial; escalation every 4 weeks in the oral phase 2 trial. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Phase 2 dose-finding, weekly injection, type 2 diabetes (NCT06542874)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (n=262) | Maintenance doses of 0.4, 1.5, 5, 10, 20 or 40 mg, escalated from 0.2 mg | Subcutaneous | Once weekly | 36 weeks | HbA1c change from -0.9% (0.4 mg) to -1.7% (40 mg); mostly mild to moderate gastrointestinal events | Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: phase 2 trial. Lancet. 2026. |
| Phase 2 dose-finding, daily tablet, type 2 diabetes (NCT06542874)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (n=186) | 6, 25 or 50 mg | Oral | Once daily | 36 weeks | HbA1c change -0.9% (6 mg), -1.3% (25 mg) and -1.4% (50 mg); all three doses beat placebo | Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: phase 2 trial. Lancet. 2026. |
| Phase 1b/2a, weekly injection, overweight or obesity (NCT06064006)Clinical trial · Randomized, placebo-controlled phase 1b/2a study | Adults aged 18–55 with overweight or obesity (n=125) | Escalated from 0.3 mg to maintenance doses of 1.25, 5, 20 or 60 mg | Subcutaneous | Once weekly | 20–36 weeks | Mean weight change -9.7% (1.25 mg, week 20), -16.2% (5 mg, week 28), -22.0% (20 mg, week 36) and -24.3% (60 mg, week 36); many participants withdrew | Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025. |
| Phase 1 first-in-human, oral (NCT05369390)Clinical trial · Randomized, double-blind, placebo-controlled phase 1 trial | Adults aged 18–55 with overweight or obesity (n=144) | Single doses of 1–25 mg; daily doses of 3–12 mg for 10 days; escalation up to 50 mg or 2 × 50 mg daily for 12 weeks | Oral | Single dose or once daily | 1 day to 12 weeks | Mild or moderate adverse events, mostly gastrointestinal, more frequent at higher doses; exposure was dose-proportional | Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1 trial. Lancet. 2025. |
Where sources disagree
- Injected and oral amycretin use very different amounts: weekly injections of 0.4–60 mg against daily tablets of 6–50 mg. A dose of one form is not a dose of the other, so no single range describes both.
- The largest weight losses come from small early-phase cohorts with many withdrawals. Phase 3 trials have not reported, and amycretin is not FDA-approved.
- Amycretin is one molecule acting on GLP-1 and amylin receptors. It is not the same as CagriSema, which combines two separate molecules, cagrilintide and semaglutide.
Handling & administration
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Appearance | White lyophilized powder |
|---|---|
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Amycretin is a single molecule that activates both the GLP-1 and amylin receptors, an approach sometimes described as unimolecular co-agonism — combining in one peptide the two satiety pathways that CagriSema addresses with two separate agents. GLP-1 receptor activation contributes glucose-dependent insulin secretion, slowed gastric emptying and central appetite suppression, while amylin receptor activation acts principally through hindbrain nuclei to reduce meal size. Both subcutaneous and oral formulations have been studied in early-phase trials. It is investigational and not approved for any use.
Origin
Synthetic unimolecular dual agonist (Novo Nordisk).
Targets
Studies
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
- Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Research statistics
16 PubMed publications · 31.3% human clinical research · 8 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Amycretin has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
How FDA approval, compounding and research-only status differ
Benefits
Amycretin side effects
The effects below are those reported in Amycretin clinical trials; long-term safety data may still be limited.
Side Effects
- GI class effects
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Amycretin: frequently asked questions
What is Amycretin?
Novo Nordisk unimolecular GLP-1 and amylin receptor agonist in oral and subcutaneous forms, advancing to Phase 3. Not FDA-approved. Distinct from CagriSema.
How does Amycretin work?
Amycretin is a single molecule that activates both the GLP-1 and amylin receptors, an approach sometimes described as unimolecular co-agonism — combining in one peptide the two satiety pathways that CagriSema addresses with two separate agents. GLP-1 receptor activation contributes glucose-dependent insulin secretion, slowed gastric emptying and central appetite suppression, while amylin receptor activation acts principally through hindbrain nuclei to reduce meal size.
Is Amycretin FDA approved?
No. Amycretin is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
Is Amycretin banned in sport?
Amycretin is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Amycretin?
Compounds most often compared with Amycretin include Cagrilintide, Pramlintide, Petrelintide and CagriSema. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial — Lancet, 2026External reference
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial — Lancet, 2026External reference
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study — Lancet, 2025External reference
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial — Lancet, 2025External reference
- Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives — Metabolism, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Amycretin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Amycretin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →